Strong US and European guidelines recommendations marks a huge success for Entresto.
By Louisa Joseph, Analyst
6 July 2016
Entresto has received the highest class I recommendation in both the US and EU chronic heart failure (CHF) treatment guidelines, recommending the drug as the first-line treatment option for CHF patients with reduced ejection fraction (HFrEF). These strong recommendations are likely to have the greatest impact in the US where the drug has experienced the slowest uptake. Entresto has struggled to gain traction within the US CHF market due to reimbursement challenges over its high yearly cost in comparison to the widely genericized ACE inhibitors/ARBs. The strength of these treatment guidelines are expected to reduce reimbursement barriers and increase physician confidence in the long-term cardiovascular benefits of treating HFrEF patients with Entresto. Additionally, the US treatment guidelines recommend Entresto to the broadest range of patients, calling for physicians to switch stable HFrEF patients with mild to moderate symptoms, from ACE inhibitors/ARBs to Entresto. These strong and broad recommendations completely redefine the standard of care for HFrEF, with Entresto likely to become the first line treatment option in the management of the disease.
Datamonitor Healthcare’s Chronic Heart Failure: marketed profiles cover the clinical and commercial attractiveness of currently branded therapies.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>